- In March 2024, Amgen Inc. announced promising clinical trial results for a new biologic therapy targeting autoimmune-related ocular inflammation, including Scleritis. This advancement is part of Amgen’s broader pipeline strategy to address rare inflammatory diseases, leveraging its expertise in monoclonal antibody development to provide targeted, long-term relief for patients suffering from vision-threatening inflammation
- In February 2024, Novartis AG initiated a phase II clinical trial evaluating the efficacy of its IL-17A inhibitor in patients with refractory non-infectious Scleritis. The trial marks a significant step toward expanding the use of systemic immunotherapies in ophthalmology, particularly for patients unresponsive to corticosteroids or conventional immunosuppressants
- In January 2024, Horizon Therapeutics plc expanded its ophthalmology portfolio by launching a compassionate access program for its TNF-α inhibitor drug, used in severe Scleritis cases associated with systemic autoimmune diseases such as rheumatoid arthritis. This program aims to improve treatment access for patients in underserved regions
- In December 2023, Celltrion Inc. received approval from the European Medicines Agency (EMA) for a biosimilar version of infliximab for ocular inflammatory conditions, including posterior Scleritis. The approval opens up more cost-effective treatment options across Europe and is expected to significantly reduce the financial burden on healthcare systems and patients
- In November 2023, Zydus Lifesciences introduced a new corticosteroid formulation with improved ocular bioavailability, specifically developed for treating anterior Scleritis. The product launch supports the growing demand for topical and minimally invasive treatment alternatives, particularly in emerging markets where access to biologics may be limited
